<SEC-DOCUMENT>0001144204-16-122992.txt : 20160907
<SEC-HEADER>0001144204-16-122992.hdr.sgml : 20160907
<ACCEPTANCE-DATETIME>20160907093022
ACCESSION NUMBER:		0001144204-16-122992
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160907
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160907
DATE AS OF CHANGE:		20160907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		161872435

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v448360_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE
COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Report (Date of Earliest Event Reported):</FONT></TD>
    <TD STYLE="text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2016</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">STAAR Surgical Company</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delaware</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>0-11634</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>95-3797439</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>1911 Walker Ave, Monrovia, California</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>91016</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s telephone number, including area code:</FONT></TD>
    <TD STYLE="text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">626-303-7902</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not Applicable</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Former name or former address, if changed
since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAAR
Surgical Company issued a press release regarding a cooperation agreement with a customer, World Eye Hospital Group (a/k/a Dunya
goz saglik hizmetleri AS</FONT>)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. A copy of the press
release is furnished as Exhibit 99.1 to this Report, and is incorporated herein by this reference. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be
&ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left"><B><U>Exhibit No.</U></B></TD><TD STYLE="text-align: justify"><B><U>Description</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press Release dated September 7, 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">STAAR Surgical Company</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">September 7, 2016</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">/s/ Caren Mason</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Caren Mason</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v448360_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>STAAR Surgical Announces Strategic
Cooperation Agreement </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>With World Eye Hospital Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>With 30,000 Refractive Procedures
Performed Annually in 21 Clinics,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>World Eye
Hospital Group is the Largest Provider in Southeast Europe</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>MONROVIA, CA, September 7, 2016</B>---STAAR
Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems
for the eye, and World Eye Hospital Group headquartered in Istanbul, Turkey<FONT STYLE="text-transform: uppercase"> </FONT>today
announced that they have entered into an agreement to provide STAAR&rsquo;s EVO Visian ICL&reg; intraocular lenses as a primary
and premium option for refractive eye treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&ldquo;World
Eye Hospital Group (D&uuml;nya G&ouml;z) is pleased to enter into this Strategic Cooperation Agreement with STAAR Surgical. As
the largest refractive eye surgery provider in Turkey and Southeast Europe, the primary goal of this agreement is to expand and
provide our patients with vision treatment services with the EVO Visian ICL technology to reduce or correct myopia, hyperopia,
and astigmatism with an outstanding vision care treatment.</FONT><FONT STYLE="color: #1F497D">&nbsp; </FONT><FONT STYLE="font-size: 10pt">We
have made the decision to offer the EVO lenses to all of our mid-to-high myopic patients as a premium procedure. We look forward
to the co-marketing, branding, clinical validation, surgeon education and patient education plans we have agreed to implement with
STAAR which will support our objective of a substantial increase in EVO refractive procedures,&rdquo; said Mr. Adem Esg&uuml;n,
Vice Chairman of The Board of World Eye Hospital Group. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;World Eye Hospital Group&rsquo;s
Head of Refractive Surgery, Dr. Efekan &Ccedil;o&#351;kunseven, is a renowned EVO ICL surgeon and will become the lead trainer
for Southeastern Europe as part of the overall agreement. EVO ICL clinical user&rsquo;s meetings and regional research studies
will enhance the development of clinical validation and new product opportunities for STAAR and World Eye Hospital Group in refractive
surgery. Practice and business development support will be foundational in this partnership&rdquo; said Caren Mason, President
&amp; CEO of STAAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I><U>About STAAR Surgical</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">STAAR, which has been dedicated solely
to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye with companion
delivery systems. These lenses are intended to provide visual freedom for patients lessening or eliminating the reliance on glasses
or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR&rsquo;s
lens used in refractive surgery is called an Implantable Collamer&reg; Lens or &ldquo;ICL&rdquo;. More than 600,000 Visian ICLs
have been implanted to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 employees and markets
lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and
Monrovia, CA. For more information, please visit the Company&rsquo;s website at www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Safe Harbor</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: statements regarding products
or potential future sales in Turkey or Southeast Europe, including but not limited to current or future sales to World Eye Hospital
Group, and any statements of assumptions related to or underlying any of the foregoing. Important factors that could cause actual
results to differ materially from those indicated by such forward-looking statements are set forth in the Company&rsquo;s Annual
Report on Form 10-K for the year ended January 1, 2016, under the caption &ldquo;Risk Factors&rdquo;, which is on file with the
Securities and Exchange Commission and available in the &ldquo;Investor Information&rdquo; section of the company&rsquo;s website
under the heading &ldquo;SEC Filings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTACT:</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Moore, 310-579-6199</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave Schemelia, 212-850-6021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug Sherk, 415-652-9100</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 40&3 P$1  (1 0,1 ?_$ +4  0 !! ,  P
M       ) 0<("@(%!@,$"P$!  ,  P$!              $" P0&!P4($
M!@(" 0,"! $'!@\    ! @,$!08 !Q$("2$2$S$402(5"E%A<9&Q,B06\(%"
M([87H<%B5"5UM38G=QB(.7DZ$0 " 0(% @,& @@%!0       0(1 R$Q$@0%
M009180?P<8$B,A.AP9&Q0E)B<B,4T>&"%0@S0R0T%O_:  P# 0 "$0,1 #\
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MZI^3+BE4*< $H_V@Y#T^H<\9QDFZTZ'U=2IC@WT>#_1F<\@D8!03 'IZC_,
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M] X'53<%]J9Q Q3 (\:8KZLC*3M91J;(1?4I?Y0#^K(2JZ&3/SP?(EYD._\
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MQ@R=G>G.[IS06X+!56R3*LW=W%"Y"'N,>Q;%391[J3!@Y3<HH%31$Z!52)I
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M;+GX(DJ8##Z!QD_%>WP*/3TJ3/Y5^61 P!@# & , 8!\9DBF'D>>?;[>>?\
M1'ZA]/H.35YK!^1"5*IXQ:R>*_06;L/7'0-MD#2UFTOK&<E#G%160D:37EWB
MRAAY,HNX&/!1<YA^HG$1'.=:Y3D;*TV[]U+^9G7]SVEVOO+SW&ZX[9SO/.3M
M0;=,L:5.]K>F=1TY0JM3UC0*VL3^PM"U"OQRY/4!_*NUCTU@X$.?[7US*YOM
M]=6FY>N./\S_ #-]GVWV_P >]6QV.UM2\86H1?X(N.5,I?XB/' "8>> _@'X
M  9QU*2S;:\S[,5ICH3>GVR.0E >/Y/P]/P_S9%?ET+")-(]4JG+( P (<X#
M50 <8(2H,$E.,5(<4RN"5@4XR:D:45R"1@# :J4 .,$)4*B'. U4 '&"4J#
M& , 8 P!@ 0YP0U4IP'\O].34C2O,J <9!9*@P!@# & , 8 P!@%!#G!#297
M!*5,!@# & , ?7 :J #C!"5!@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
E@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
